NASDAQ:RLYB Rallybio Q3 2024 Earnings Report $16.62 +0.01 (+0.06%) Closing price 04:00 PM EasternExtended Trading$16.77 +0.15 (+0.93%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rallybio EPS ResultsActual EPS-$2.08Consensus EPS -$2.88Beat/MissBeat by +$0.80One Year Ago EPSN/ARallybio Revenue ResultsActual Revenue$0.30 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARallybio Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time8:00AM ETUpcoming EarningsRallybio's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Rallybio Earnings HeadlinesRallybio CFO Transition Amid Pending Avenzo Therapeutics MergerSeptember 9, 2026 | tipranks.comRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 25 at 1:00 AM | Profits Run (Ad)RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?June 1, 2026 | finance.yahoo.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its ShareholdersJune 1, 2026 | businesswire.comRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementJune 1, 2026 | businesswire.comSee More Rallybio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email. Email Address About RallybioRallybio (NASDAQ:RLYB) (NASDAQ:RLYB) is a clinical-stage biotechnology company focused on developing therapies for rare diseases and conditions with significant unmet medical needs. The company seeks to address disorders in which relatively small patient populations may face limited treatment options. Rallybio’s pipeline has included RLYB212, an investigational antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia, a potentially serious condition that can occur when maternal antibodies attack fetal platelets. The company has also pursued early-stage programs involving complement biology and other disease mechanisms. Rallybio was founded in 2018 and is based in New Haven, Connecticut. Its development activities are primarily focused on advancing drug candidates through clinical and preclinical research, with the goal of potentially serving patients in the United States and international markets if its therapies receive regulatory approval.View Rallybio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
